Richard Haubrich

Title(s)Emeritus Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Screening for atherosclerotic vascular disease in HIV-infected children
    NIH R01HD083042Mar 25, 2015 - Feb 28, 2021
    Role: Co-Principal Investigator
    Assessing the Clinical Consequences of HIV Drug Resistance
    NIH R21AI080397Sep 25, 2008 - Aug 31, 2011
    Role: Principal Investigator
    Improving Antiretroviral Management for HIV
    NIH K24AI064086Jan 1, 2005 - Feb 28, 2016
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year. Future Microbiol. 2024; 19(15):1273-1282. Esser S, Inciarte A, Levy I, D'Arminio Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito M, Liu CE, Aydin OA, Thorpe D, Heinzkill M, Marongiu A, Cassidy T, Haubrich R, D'Amato L, Robineau O. PMID: 39229785.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies. Clin Infect Dis. 2024 Jun 26. Fusco D, Malenica I, Günthard HF, Gupta SK, Kurbegov D, Balani B, Olender S, Aberg JA, Telep LE, Tian Y, Blair C, Wu G, Haubrich R, Wang CY, Chokkalingam AP, Osinusi AO, Wendtner CM, Gottlieb RL. PMID: 38920297.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts. HIV Med. 2024 04; 25(4):440-453. Esser S, Brunetta J, Inciarte A, Levy I, D'Arminio Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito M, Liu CE, Altuntas Aydin O, Thorpe D, Heinzkill M, Marongiu A, Cassidy T, Haubrich R, D'Amato L, Robineau O. PMID: 38148567.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection. AIDS. 2024 03 15; 38(4):607-610. VanderVeen LA, Selzer L, Moldt B, Parvangada A, Li J, Ananworanich J, Crowell TA, Eron JJ, Daar ES, Haubrich R, Geleziunas R, Cyktor J, Mellors JW, Callebaut C. PMID: 38416554; PMCID: PMC10906214.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    5. Prevalence of and risk factors for Human Immunodeficiency Virus (HIV) infection in entrants and residents of an Ethiopian prison. PLoS One. 2023; 18(2):e0271666. Sahle ET, Amogne W, Manyazewal T, Blumenthal J, Jain S, Sun S, Young J, Ellorin E, Woldeamanuel H, Teferra L, Feleke B, Vandenberg O, Rey Z, Briggs-Hagen M, Haubrich R, McCutchan JA. PMID: 36758059; PMCID: PMC9910692.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clin Infect Dis. 2022 08 24; 75(1):e450-e458. Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R. PMID: 34596223; PMCID: PMC9402660.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    7. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. HIV Med. 2023 01; 24(1):27-36. Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. PMID: 35527425; PMCID: PMC10083930.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    8. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clin Infect Dis. 2021 12 06; 73(11):e4166-e4174. Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Hu H, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Diaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, Bernardino JI, GS-US-540–5773 and GS-US-540–5807 Investigators. PMID: 32706859; PMCID: PMC7454434.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCellsCTClinical Trials
    9. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021 10 05; 73(7):1149-1156. Blumenthal J, Jain S, He F, Amico KR, Kofron R, Ellorin E, Stockman JK, Psaros C, Ntim GM, Chow K, Anderson PL, Haubrich R, Corado K, Moore DJ, Morris S, Landovitz RJ. PMID: 33864370; PMCID: PMC8492205.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    10. Reply to Pandita et al. Clin Infect Dis. 2021 07 15; 73(2):357. Olender SA, Perez KK, Chokkalingam AP, Haubrich RH. PMID: 32894754; PMCID: PMC8282261.
      View in: PubMed   Mentions:    Fields:    
    11. Pilot comparison of the ease of swallowing of single tablet antiretroviral regimens. AIDS Care. 2022 03; 34(3):404-407. Parraga Acosta T, Osborn Z, Lee JC, Haubrich RH, McNicholl I, McKinnon JE. PMID: 34125632.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. J Acquir Immune Defic Syndr. 2021 04 01; 86(4):490-495. Perez-Valero I, Llibre JM, Castagna A, Pulido F, Molina JM, Esser S, Margot N, Shao Y, Temme L, Piontkowsky D, McNicholl IR, Haubrich R. PMID: 33315694; PMCID: PMC7899215.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    13. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infect Dis Ther. 2021 Jun; 10(2):775-788. Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. PMID: 33686573; PMCID: PMC8116430.
      View in: PubMed   Mentions: 16  
    14. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. AIDS. 2021 03 01; 35(3):407-417. Brooks KM, Momper JD, Pinilla M, Stek AM, Barr E, Weinberg A, Deville JG, Febo IL, Cielo M, George K, Denson K, Rungruengthanakit K, Shapiro DE, Smith E, Chakhtoura N, Rooney JF, Haubrich R, Espina R, Capparelli EV, Mirochnick M, Best BM, IMPAACT P1026s Protocol Team. PMID: 33252495; PMCID: PMC8238253.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs. J Antimicrob Chemother. 2020 08 01; 75(8):2249-2252. Margot N, Ram R, McNicholl I, Haubrich R, Callebaut C. PMID: 32413134.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    16. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clin Infect Dis. 2020 05 06; 70(10):2131-2140. Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L, EuroSIDA Study. PMID: 31504296.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    17. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V. Antimicrob Agents Chemother. 2020 03 24; 64(4). Margot N, Ram R, Abram M, Haubrich R, Callebaut C. PMID: 31988104; PMCID: PMC7179327.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    18. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS One. 2020; 15(1):e0224875. Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, Goldstein D, Applin S, Ryu JH, Jiang S, Cox S, Das M, Nguyen-Cleary T, Piontkowsky D, Guyer B, Rossaro L, Haubrich RH. PMID: 31995556; PMCID: PMC6988963.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. Bacteriologically-confirmed pulmonary tuberculosis in an Ethiopian prison: Prevalence from screening of entrant and resident prisoners. PLoS One. 2019; 14(12):e0226160. Tsegaye Sahle E, Blumenthal J, Jain S, Sun S, Young J, Manyazewal T, Woldeamanuel H, Teferra L, Feleke B, Vandenberg O, Rey Z, Briggs-Hagen M, Haubrich R, Amogne W, McCutchan JA. PMID: 31830092; PMCID: PMC6907752.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsPHPublic Health
    20. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019 10; 6(10):e655-e666. Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, Ong E, Shao Y, Piontkowsky D, Das M, McNicholl I, Haubrich R. PMID: 31578954.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    21. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. AIDS. 2019 08 01; 33(10):1583-1593. Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH. PMID: 31305329.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    22. Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. AIDS Patient Care STDS. 2019 05; 33(5):220-226. Blumenthal J, Moore DJ, Jain S, Sun X, Ellorin E, Corado K, Hoenigl M, Dube M, Haubrich R, Morris SR. PMID: 31067122; PMCID: PMC6531901.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    23. Perceived Versus Calculated HIV Risk: Implications for Pre-exposure Prophylaxis Uptake in a Randomized Trial of Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):e23-e29. Blumenthal J, Jain S, Mulvihill E, Sun S, Hanashiro M, Ellorin E, Graber S, Haubrich R, Morris S. PMID: 30422909; PMCID: PMC6331232.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansPHPublic Health
    24. Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):e9-e13. Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR, CCTG Team. PMID: 30334877; PMCID: PMC6289757.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    25. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis. 2018 05 02; 66(10):1566-1572. Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR. PMID: 29228144; PMCID: PMC6248545.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansPHPublic Health
    26. Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. PLoS One. 2018; 13(1):e0190438. Kearney MF, Spindler J, Wiegand A, Shao W, Haubrich R, Riddler S, Lalama CM, Hughes MD, Coffin JM, Mellors JW. PMID: 29370196; PMCID: PMC5784902.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    27. Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation. Clin Pharmacol Ther. 2018 03; 103(3):502-510. Browne SH, Peloquin C, Santillo F, Haubrich R, Muttera L, Moser K, Savage GM, Benson CA, Blaschke TF. PMID: 28597911; PMCID: PMC5836848.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    28. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. J Infect Dis. 2017 09 01; 216(5):554-564. Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW, AIDS Clinical Trials Group. PMID: 28931220; PMCID: PMC5853681.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    29. Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine (Baltimore). 2017 Apr; 96(14):e6275. Drozd DR, Saag MS, Westfall AO, Mathews WC, Haubrich R, Boswell SL, Cole SR, Porter D, Kitahata MM, Juday T, Rosenblatt L, CFAR Network of Integrated Clinical Systems (CNICS). PMID: 28383402; PMCID: PMC5411186.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clin Trials. 2017 03; 18(2):67-74. Karris MY, Jain S, Day TR, Pérez-Santiago J, Goicoechea M, Dubé MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S, California Collaborative Treatment Group (CCTG) 589 Study Team. PMID: 28134057; PMCID: PMC5613656.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    31. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 2016 12 01; 45(6):2038-2049. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, D'Arminio Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Cli. PMID: 26721599; PMCID: PMC5841611.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    32. Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men. AIDS Behav. 2016 06; 20(6):1173-1181. Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R, CCTG 592 Team. PMID: 26487300; PMCID: PMC4838553.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    33. Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):e48-50. Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S, California Collaborative Treatment Group (CCTG) 589 Study Team. PMID: 26977746; PMCID: PMC4867124.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Impact of pre-adapted HIV transmission. Nat Med. 2016 06; 22(6):606-13. Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA. PMID: 27183217; PMCID: PMC4899163.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    35. High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J. 2016 Jan; 35(1):e1-7. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. PMID: 26421804; PMCID: PMC4707556.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS One. 2015; 10(12):e0144767. Paris RM, Petrovas C, Ferrando-Martinez S, Moysi E, Boswell KL, Archer E, Yamamoto T, Ambrozak D, Casazza JP, Haubrich R, Connors M, Ake J, Kim JH, Koup RA. PMID: 26678998; PMCID: PMC4692060.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    37. HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med. 2015 Dec 15; 163(12):908-17. Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH, A5241 Study Team. PMID: 26595748; PMCID: PMC4681296.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    38. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep. 2015 Aug 24; 5:13179. Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR. PMID: 26299251; PMCID: PMC4547398.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    39. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015 08; 16(4):147-56. Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH. PMID: 26212575; PMCID: PMC4640927.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    40. Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. AIDS Behav. 2015 May; 19(5):802-10. Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, Haubrich R, CCTG 598 Team. PMID: 25616837; PMCID: PMC4417031.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansPHPublic Health
    41. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics. 2015 Feb; 25(2):51-9. Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ. PMID: 25461247; PMCID: PMC4387236.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    42. Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis. 2015 Jan; 2(1):ofu113. Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW. PMID: 25884002; PMCID: PMC4396430.
      View in: PubMed   Mentions: 24  
    43. Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):73-80. Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Jacobson DL. PMID: 25321179; PMCID: PMC4262682.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    44. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure. J Clin Virol. 2015 Jan; 62:48-53. Fisher RG, Smith DM, Murrell B, Slabbert R, Kirby BM, Edson C, Cotton MF, Haubrich RH, Kosakovsky Pond SL, Van Zyl GU. PMID: 25542470; PMCID: PMC4279108.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsPHPublic Health
    45. Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor. 2014 Nov 01; 16(11):909-15. Blumenthal J, Haubrich RH. PMID: 25397651; PMCID: PMC4308722.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansPHPublic Health
    46. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. PMID: 24842909; PMCID: PMC4155445.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    47. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014 Jul; 88(14):7818-27. Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM, California Collaborative Treatment Group 592 Team. PMID: 24789781; PMCID: PMC4097769.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    48. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression. Antiviral Res. 2014 Jul; 107:42-9. Beliakova-Bethell N, Jain S, Woelk CH, Witt MD, Sun X, Lada SM, Spina CA, Goicoechea M, Rought SE, Haubrich R, Dubé MP. PMID: 24769244; PMCID: PMC4116489.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    49. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014 Jun; 58(11):1599-606. Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, Moore RD, Haubrich RH, Gopal S, Eron JJ, Hunt PW, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). PMID: 24523217; PMCID: PMC4017888.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    50. Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART. Int J STD AIDS. 2014 Sep; 25(10):734-41. Blumenthal J, Haubrich R, Jain S, Sun X, Dube M, Daar E, Milam J, Morris S. PMID: 24452730; PMCID: PMC4303352.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    51. Community HIV-1 drug resistance is associated with transmitted drug resistance. HIV Med. 2014 Jul; 15(6):339-46. Tilghman MW, Pérez-Santiago J, Osorio G, Little SJ, Richman DD, Mathews WC, Haubrich RH, Smith DM. PMID: 24417811; PMCID: PMC4055747.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    52. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014 Apr; 58(7):1015-22. Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA. PMID: 24352352; PMCID: PMC3952601.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    53. An intervention study examining the effects of condom wrapper graphics and scent on condom use in the Botswana Defence Force. AIDS Care. 2014; 26(7):890-8. Tran BR, Thomas AG, Vaida F, Ditsela M, Phetogo R, Kelapile D, Haubrich R, Chambers C, Shaffer R. PMID: 24266459; PMCID: PMC3991928.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Suppressed but still infectious. Future Virol. 2013; 8(11):1037-1040. Gianella S, Haubrich R, Morris SR. PMID: 39640894; PMCID: PMC11619922.
      View in: PubMed   Mentions:
    55. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Infect Dis. 2013 Dec; 57(11):1607-17. Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM. PMID: 24046302; PMCID: PMC3814827.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    56. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials. 2013 Sep-Oct; 14(5):224-34. Huang JS, Hughes MD, Riddler SA, Haubrich RH, Aids Clinical Trials Group A5142 Study Team. PMID: 24144899; PMCID: PMC3956746.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    57. Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis. 2014 Feb 01; 209(3):452-6. Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM. PMID: 23964106; PMCID: PMC3883163.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    58. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013 Nov; 57(10):1483-8. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT. PMID: 23943825; PMCID: PMC3805172.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    59. Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. Expert Opin Pharmacother. 2013 Sep; 14(13):1777-85. Blumenthal J, Haubrich R. PMID: 23800167; PMCID: PMC3954121.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    60. Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children. Pediatr Infect Dis J. 2013 Jun; 32(6):e254-62. Innes S, Schulte-Kemna E, Cotton MF, Zöllner EW, Haubrich R, Klinker H, Sun X, Jain S, Edson C, van Niekerk M, Innes ER, Rabie H, Browne SH. PMID: 23249919; PMCID: PMC4000309.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis. 2013 Aug; 57(3):441-7. Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang F, Ginocchio CC, Haubrich RH, Morris SR, CCTG 592 Team. PMID: 23595831; PMCID: PMC3703105.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    62. High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 2012 Nov 23; 12:183. Innes S, Cotton MF, Haubrich R, Conradie MM, van Niekerk M, Edson C, Rabie H, Jain S, Sun X, Zöllner EW, Hough S, Browne SH. PMID: 23176441; PMCID: PMC3584923.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    63. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):381-9. Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL. PMID: 22828718; PMCID: PMC3480980.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    64. Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol. 2012 Dec; 86(24):13202-16. Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL, International HIV Adaptation Collaborative. PMID: 23055555; PMCID: PMC3503140.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    65. Characterizing HIV transmission networks across the United States. Clin Infect Dis. 2012 Oct; 55(8):1135-43. Aldous JL, Pond SK, Poon A, Jain S, Qin H, Kahn JS, Kitahata M, Rodriguez B, Dennis AM, Boswell SL, Haubrich R, Smith DM. PMID: 22784872; PMCID: PMC3529609.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    66. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011 Nov 28; 25(18):2269-78. Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW, AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams. PMID: 21941167; PMCID: PMC3572727.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    67. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):253-60. Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS, AIDS Clinical Trial Group DACS 241 Team, AIDS Clinical Trial Group Study 5095 Team, AIDS Clinical Trial Group Study 5142 team, Antiretroviral Cohort Collaboration. PMID: 21857357; PMCID: PMC3196673.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    68. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep-Oct; 12(5):277-85. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A, Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. PMID: 22180526; PMCID: PMC3322423.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    69. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011 Aug 15; 204(4):515-20. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ. PMID: 21791652; PMCID: PMC3203388.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    70. Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol. 2011 Sep 01; 187(5):2502-13. Almeida CA, Bronke C, Roberts SG, McKinnon E, Keane NM, Chopra A, Kadie C, Carlson J, Haas DW, Riddler SA, Haubrich R, Heckerman D, Mallal S, John M. PMID: 21821798; PMCID: PMC3183574.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    71. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One. 2011; 6(6):e21189. Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. PMID: 21701595; PMCID: PMC3118815.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    72. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc. 2011 May 08; 9:5. Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, Haubrich RH. PMID: 21548986; PMCID: PMC3117802.
      View in: PubMed   Mentions: 3  
    73. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):344-8. Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW, AIDS Clinical Trials Group Study A5142 Protocol Team. PMID: 21350368; PMCID: PMC3086845.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    74. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood. 2011 May 05; 117(18):4805-15. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, Gostick E, Katsikis PD, Douek DC, Haubrich R, Petrovas C, Koup RA. PMID: 21398582; PMCID: PMC3100691.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCellsCTClinical Trials
    75. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis. 2011 Jan 15; 52(2):264-70. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. PMID: 21288854; PMCID: PMC3106253.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    76. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011 Jan 02; 25(1):37-47. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. PMID: 20871389; PMCID: PMC2995830.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    77. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput. 2011; 253-64. Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD. PMID: 21121053; PMCID: PMC3094912.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    78. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 Feb; 66(2):354-7. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I, CHARTER Group. PMID: 21098541; PMCID: PMC3019085.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    79. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, et al. PMID: 21051598; PMCID: PMC3235490.
      View in: PubMed   Mentions: 705     Fields:    Translation:HumansCells
    80. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):394-7. Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, Mayer H, Valdez H. PMID: 20009949.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    81. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol. 2010 Apr 15; 184(8):4368-77. John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D, Haas DW, Riddler SA, Haubrich R, Mallal S. PMID: 20231689; PMCID: PMC3011274.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    82. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS. 2010 Mar 13; 24(5):707-16. Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R, California Collaborative Treatment Group. PMID: 20087154.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    83. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr. 2010 Feb; 53(2):194-201. May S, Gamst A, Haubrich R, Benson C, Smith DM. PMID: 19770802; PMCID: PMC2915780.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    84. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W, Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J. PMID: 21041921.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    85. Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation. J Clin Pharmacol. 2010 Aug; 50(8):968-74. Goicoechea M, Jain S, Bi L, Sun S, Smith G, Ha B, Richman D, Louie S, Haubrich R, California Collaborative Treatment Group. PMID: 19952374.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    86. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13; 23(17):2289-300. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G, DUET-1, DUET-2 study groups. PMID: 19710593.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    87. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009 Nov; 4(6):459-66. Aldous JL, Haubrich RH. PMID: 20048711; PMCID: PMC2946177.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    88. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS. 2009 Oct 23; 23(16):2151-8. Smith DM, May SJ, Pérez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, Richman DD, Benson CA, Little SJ. PMID: 19730348; PMCID: PMC2915784.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    89. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009 Aug 19; 4(8):e6687. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S. PMID: 19690614; PMCID: PMC2723923.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCells
    90. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009 Jun 01; 23(9):1109-18. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV, AIDS Clinical Trials Group (ACTG) A5142 Study Team. PMID: 19417580; PMCID: PMC2739977.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCellsCTClinical Trials
    91. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009 Jun; 53(6):2335-41. Eron JJ, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD, ACTG5126 Study Team. PMID: 19307363; PMCID: PMC2687257.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    92. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Futur HIV Ther. 2008 Nov 01; 2(6):525-537. Minuto JJ, Haubrich R. PMID: 19881888; PMCID: PMC2770189.
      View in: PubMed   Mentions: 4  
    93. Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. HIV Clin Trials. 2008 Sep-Oct; 9(5):348-65. Haubrich R, Soriano V, Lafeuillade A. PMID: 18977724.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    94. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008 Jun; 46(4):393-5. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, McCutchan JA, Larsen RA. PMID: 18415850.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    95. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15; 358(20):2095-106. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team. PMID: 18480202; PMCID: PMC3885902.
      View in: PubMed   Mentions: 226     Fields:    Translation:HumansCellsCTClinical Trials
    96. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses. 2008 May; 24(5):685-94. Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM, AIDS Clinical Trials Group Study 359 Protocol Team. PMID: 18462083; PMCID: PMC2928289.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    97. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008 Oct; 37(5):948-55. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, Lober WB, Van Rompaey SE, Crane HM, Moore RD, Bertram M, Kahn JO, Saag MS. PMID: 18263650; PMCID: PMC2597168.
      View in: PubMed   Mentions: 211     Fields:    Translation:Humans
    98. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008 Feb 01; 197(3):411-9. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK. PMID: 18248304.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    99. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008 Jan 01; 197(1):102-8. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 Team. PMID: 18171292.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    100. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 Dec 01; 46(4):433-42. Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH, California Collaborative Treatment Group 578 Study Team. PMID: 17786128.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    101. Defining HIV susceptibility to new antiretroviral agents--darunavir. J Infect Dis. 2007 Oct 15; 196(8):1125-7. Haubrich R. PMID: 17955429.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    102. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):29-38. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, DUET-1 study group. PMID: 17617270.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCellsCTClinical Trials
    103. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 Apr 07; 369(9568):1169-78. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E, POWER 1 and 2 study groups. PMID: 17416261.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCells
    104. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007 Mar 30; 21(6):F11-8. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, van Baelen B, Lefebvre E, POWER 2 Study Group. PMID: 17413685.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    105. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin Trials. 2007 Mar-Apr; 8(2):63-7. Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM, AIDS Clinical Trials Group Protocol 359 Team. PMID: 17507321.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    106. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar; 2(1):97-104. May S, Letendre S, Haubrich R, McCutchan JA, Heaton R, Capparelli E, Ellis R. PMID: 18040832.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    107. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring. Antivir Ther. 2007; 12(1):55-62. Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, Witt MD, Haubrich R, California Collaborative Treatment Group. PMID: 17503748.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    108. A practical method to calibrate self-reported adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 Dec 01; 43 Suppl 1:S104-12. Liu H, Miller LG, Hays RD, Wagner G, Golin CE, Hu W, Kahn K, Haubrich R, Kaplan AH, Wenger NS. PMID: 17133192.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    109. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use. AIDS. 2006 Oct 24; 20(16):2127-8. Goicoechea M, Best B, Capparelli E, Caperna J, Ballard C, Haubrich R. PMID: 17053363.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations. Clin Infect Dis. 2006 Jul 01; 43(1):116-7. Goicoechea M, Best B, Capparelli E, Haubrich R, California Collaborative Treatment Group. PMID: 16758435.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006 Jun 12; 20(9):1295-302. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, Diamond C, Tilles JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH. PMID: 16816559.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    112. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006 Jul 01; 194(1):29-37. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R. PMID: 16741879.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    113. Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression. AIDS Patient Care STDS. 2006 Apr; 20(4):233-7. Goicoechea M, Best B, Seefried E, Wagner G, Capparelli E, Haubrich R, California Collaborative Treatment Group (CCTG). PMID: 16623621.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    114. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. Expert Opin Investig Drugs. 2006 Jan; 15(1):59-70. Best B, Haubrich R. PMID: 16370934.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    115. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005 Nov 01; 40(3):301-6. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. PMID: 16249704.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    116. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005 Jul-Aug; 6(4):187-96. Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, Haubrich R. PMID: 16214735.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    117. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18; 19(3):295-302. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD, California Collaborative Treatment Group. PMID: 15718840.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    118. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther. 2004 Oct; 9(5):753-61. Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH, California Collaborative Treatment Group. PMID: 15535413.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    119. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004 Sep 01; 190(5):886-93. Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM, AIDS Clinical Trials Group Protocol 359 Team. PMID: 15295692.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    120. Resistance and replication capacity assays: clinical utility and interpretation. Top HIV Med. 2004 May-Jun; 12(2):52-6. Haubrich RH. PMID: 15184711.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    121. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004 Apr 01; 189(7):1176-84. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. PMID: 15031785.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCellsCTClinical Trials
    122. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2304-15. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team. PMID: 14668456; PMCID: PMC4768873.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCellsCTClinical Trials
    123. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther. 2003 Dec; 8(6):489-506. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD. PMID: 14760883.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    124. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther. 2003 Aug; 8(4):279-87. Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J. PMID: 14518696.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    125. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003 Apr 15; 187(8):1327-31. Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, Deresinski SC, California Collaborative Treatment Group. PMID: 12696015.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    126. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002 Oct 18; 16(15):F33-40. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA, California Collaborative Treatment Group. PMID: 12370520.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    127. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002 Sep 01; 186(5):626-33. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. PMID: 12195349.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    128. Early adoption of HIV-1 resistance testing in the San Diego County Ryan White CARE Act Program: predictors and outcome. AIDS Patient Care STDS. 2002 Jul; 16(7):337-48. Mathews WC, Cole J, Ballard C, Colwell B, Haubrich R, Barber E, Lew T. PMID: 12214573.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    129. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr. 2002 Jun 01; 30(2):154-8. Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour HH, AIDS Clinical Trial Group 722 Study Team. PMID: 12045677.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    130. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002 Mar; 16 Suppl 1:S5-37. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF. PMID: 12035820.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    131. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother. 2001 Dec; 45(12):3663-8. Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS. PMID: 11709366; PMCID: PMC90895.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    132. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001 Oct 01; 33(7):1060-8. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, McCutchan JA, California Collaborative Treatment Group. PMID: 11528581.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    133. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Antivir Ther. 2001 Jun; 6(2):89-96. Schooley RT, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME, Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P. PMID: 11491421.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    134. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antivir Ther. 2001 Jun; 6(2):105-14. McMahon D, Lederman M, Haas DW, Haubrich R, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors JW. PMID: 11491415.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    135. Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus. J Acquir Immune Defic Syndr. 2001 Jun 01; 27(2):210-1. Becker S, Fisher A, Flexner C, Gerber JG, Haubrich R, Kashuba AD, Luber AD, Piscitelli SC. PMID: 11404545.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    136. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr. 2001 Apr 15; 26(5):458-61. Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L, Tisdale M. PMID: 11391165.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    137. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001 Mar 30; 15(5):609-15. Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R, California Collaborative Treatment Group #575 Team. PMID: 11316998.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    138. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr. 2001 Mar 01; 26 Suppl 1:S3-9. Demeter L, Haubrich R. PMID: 11264997.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    139. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr. 2001 Mar 01; 26 Suppl 1:S51-9. Haubrich R, Demeter L. PMID: 11265001.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    140. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000 Dec 01; 14(17):2635-42. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W. PMID: 11125881.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsCTClinical Trials
    141. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. AIDS. 2000 Nov 10; 14(16):2495-501. Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM, ACTG Protocol Team. PMID: 11101060.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    142. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000 Nov; 182(5):1375-84. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. PMID: 11023461.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    143. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. AIDS Res Hum Retroviruses. 2000 Jul 20; 16(11):1031-7. Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, Haubrich R, Liou S. PMID: 10933617.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    144. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels. AIDS. 2000 Apr 14; 14(6):746-8. Sha BE, Johnson VA, Kendall MA, Haubrich R, Nokta M, Lamb K, Zackin RA, Nail CD, Currier JS. PMID: 10807200.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    145. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000 Feb; 181(2):522-31. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. PMID: 10669335.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsPHPublic Health
    146. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS. 1999 Dec 03; 13(17):2411-20. Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N. PMID: 10597783.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    147. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999 Oct; 180(4):1338-41. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. PMID: 10479168.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    148. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 Jun 18; 13(9):1099-107. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé MP, Hwang JY, McCutchan JA. PMID: 10397541.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCellsCTClinical Trials
    149. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia. JAMA. 1999 Jan 13; 281(2):130-1. Haubrich R, Richman D. PMID: 9917108.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antivir Ther. 1999; 4(1):35-44. Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC. PMID: 10682127.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    151. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct; 49(4):421-32. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. PMID: 9876338.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    152. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis. 1998 Mar; 177(3):595-9. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. PMID: 9498437.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    153. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 May 01; 15(1):28-34. Fischl MA, Richman DD, Flexner C, Para MF, Haubrich R, Karim A, Yeramian P, Holden-Wiltse J, Meehan PM. PMID: 9215651.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    154. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10; 335(15):1081-90. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. PMID: 8813038.
      View in: PubMed   Mentions: 186     Fields:    Translation:HumansCTClinical Trials
    155. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis. 1996 Apr; 173(4):942-9. Torriani FJ, Behling CA, McCutchan JA, Haubrich RH, Havlir DV. PMID: 8603975.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    156. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis. 1996 Feb; 22(2):322-8. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MA, Haubrich RH, Richie JA, Edwards JE, Ghannoum MA. PMID: 8838190.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimals
    157. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov; 172(5):1246-52. Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD. PMID: 7594660.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    158. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects. Hum Gene Ther. 1995 Jul; 6(7):941-55. Haubrich R, McCutchan JA, Holdredge R, Heiner L, Merritt J, Merchant B. PMID: 7578412.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    159. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis. 1994 Jul; 170(1):238-42. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA. PMID: 8014509.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    Richard's Networks
    Concepts (472)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (71)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California